Who enrolls in the medicare part D prescription drug benefit program? Medication use among patients with heart failure

Journal of the American Heart Association

Volumn 2, Issue 5, 2013, Pages

  Eapen, Zubin J ^a,b   Hammill, Bradley G ^a   Setoguchi, Soko ^a,b   Schulman, Kevin A ^a,b   Peterson, Eric D ^a,b   Hernandez, Adrian F ^a,b   Curtis, Lesley H ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; Medicare Part D; Outcome assessment (health care)

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; PRESCRIPTION DRUG;

AGED; ARTICLE; BLACK PERSON; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; FEMALE; HEALTH INSURANCE; HEALTH PROGRAM; HEALTH SERVICE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; POPULATION RESEARCH; PRESCRIPTION; SOCIAL STATUS; VERY ELDERLY; DRUG UTILIZATION; STATISTICS AND NUMERICAL DATA; UNITED STATES; UTILIZATION; OUTCOME ASSESSMENT; STATISTICS; UTILIZATION REVIEW;

AGED, 80 AND OVER; DRUG UTILIZATION; FEMALE; HEART FAILURE; HUMANS; MALE; MEDICARE PART D; PRESCRIPTION DRUGS; UNITED STATES;

HEART FAILURE; MEDICARE PART D; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84891684757     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.113.000242     Document Type: Article

References (32)

1. Stevenson LW. Projecting heart failure into bankruptcy in 2012? Am Heart J. 2011;161:1007-1011.
2. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297:1233-1240.
3. Tinetti ME, Studenski SA. Comparative effectiveness research and patients with multiple chronic conditions. N Engl J Med. 2011;364:2478-2481.
4. Curtis LH, Whellan DJ, Hammill BG, Hernandez AF, Anstrom KJ, Shea AM, Schulman KA. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med. 2008;168:418-424.
5. Bonow RO, Bennett S, Casey DE Jr, Ganiats TG, Hlatky MA, Konstam MA, Lambrew CT, Normand SL, Pina IL, Radford MJ, Smith AL, Stevenson LW, Burke G, Eagle KA, Krumholz HM, Linderbaum J, Masoudi FA, Ritchie JL, Rumsfeld JS, Spertus JA; American College of Cardiology; American Heart Association Task Force on Performance Measures; Heart Failure Society of America. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society of America. Circulation. 2005;112:1853-1887.
6. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005;43:480-485.
7. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139.
8. Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002). Stroke. 2006;37:1969-1974.
9. Schneider KM, O'Donnell BE, Dean D. Prevalence of multiple chronic conditions in the United States' Medicare population. Health Qual Life Outcomes. 2009;7:82.
10. Pfeffer MA, Braunwald E, Moye LA, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
11. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
12. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
13. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682-1688.
14. Saczynski JS, Darling CE, Spencer FA, Lessard D, Gore JM, Goldberg RJ. Clinical features, treatment practices, and hospital and long-term outcomes of older patients hospitalized with decompensated heart failure: the Worcester Heart Failure Study. J Am Geriatr Soc. 2009;57:1587-1594.
15. Deswal A, Petersen NJ, Urbauer DL, Wright SM, Beyth R. Racial variations in quality of care and outcomes in an ambulatory heart failure cohort. Am Heart J. 2006;152:348-354.
16. Joynt KE, Orav EJ, Jha AK. Thirty-day readmission rates for medicare beneficiaries by race and site of care. JAMA. 2011;305:675-681.
17. Philbin EF, Dec GW, Jenkins PL, DiSalvo TG. Socioeconomic status as an independent risk factor for hospital readmission for heart failure. Am J Cardiol. 2001;87:1367-1371.
18. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu AW. Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226-1233.
19. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: The National Academies Press; 2009.
20. DiMartino LD, Shea AM, Hernandez AF, Curtis LH. Use of guideline-recommended therapies for heart failure in the medicare population. Clin Cardiol. 2010;33:400-405.
21. Kramer JM, Chen AY, Hammill BG, DeLong ER, LaPointe NA, Muhlbaier LH, McCants CB, Califf RM. Time trends and factors associated with outpatient beta-blocker use in patients with heart failure or left ventricular dysfunction [abstract]. Circulation. 2004;109:e231-e284.
22. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391-e479.
23. Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA. 2008;300:431-433.
24. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S. Clinical characteristics and outcomes of heart failure with preserved ejection fraction: lessons from epidemiological studies. J Cardiol. 2010;55:13-22.
25. Hernandez AF, Mi X, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Qualls LG, Peterson ED, Fonarow GC, Curtis LH. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA. 2012;308: 2097-2107.
26. Curtis LH, Mi X, Qualls LG, Check DK, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Setoguchi S, Hernandez AF, Fonarow GC. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am Heart J. 2013;165:979.e1-986.e1.
27. Zhang Y, Donohue JM, Newhouse JP, Lave JR. The effects of the coverage gap on drug spending: a closer look at Medicare Part D. Health Aff (Millwood). 2009;28:w317-w325.
28. Hales JW, George S. How the doughnut hole affects prescription fulfillment decisions involving cardiovascular medications for Medicare Part D enrollees. Manag Care. 2010;19:36-44.
29. Donohue JM, Zhang Y, Lave JR, Gellad WF, Men A, Perera S, Hanlon JT. The Medicare drug benefit (Part D) and treatment of heart failure in older adults. Am Heart J. 2010;160:159-165.
30. Polinski JM, Shrank WH, Glynn RJ, Huskamp HA, Roebuck MC, Schneeweiss S. Beneficiaries with cardiovascular disease and the Part D coverage gap. Circ Cardiovasc Qual Outcomes. 2012;5:387-395.
31. Potetz L, Cubanski J, Neuman T. Medicare Spending and Financing: A Primer. Washington, DC: Kaiser Family Foundation; February 2011. Available at: http://www.kff.org/medicare/upload/7731-03.pdf. Accessed January 6, 2012.
32. Stuart B, Loh FE. Medicare Part D enrollees' use of out-of-plan discounted generic drugs. J Am Geriatr Soc. 2012;60:387-388.